• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Equillium Inc.

    5/29/26 4:05:29 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQ alert in real time by email
    8-K
    NASDAQ false 0001746466 0001746466 2026-05-28 2026-05-28
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 28, 2026

     

     

    Equillium, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-38692   82-1554746

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    2223 Avenida de la Playa  
    Suite 105  
    La Jolla, CA   92037
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (858) 240-1200

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.0001 per share   EQ   The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On May 28, 2026, Equillium, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 1, 2026, the record date for the Annual Meeting (the “Record Date”), 63,226,556 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

    A total of 54,287,329 shares of the Company’s common stock were present at the Annual Meeting or represented by proxy, which represents approximately 85.86% of the shares of the Company’s common stock outstanding as of the Record Date.

    Proposal 1. Election of directors.

    The Company’s stockholders elected the two persons listed below as Class II directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successor has been duly elected and qualified, or until their earlier death, resignation or removal. Former director Peter Colabuono was not renominated as a director and his term ended at the Annual Meeting. In connection with the expiration of Mr. Colabuono’s term, the Company reduced the size of the Board of Directors from seven directors to six directors. The final voting results are as follows:

     

    Name    Votes For      Votes Withheld      Broker Non-
    Votes

    Charles McDermott

       36,072,238      10,018,889      8,196,202

    Bruce Steel

       45,955,052      136,075      8,196,202

    Proposal 2. Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split.

    The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-20, inclusive, with such ratio to be determined in the discretion of the Company’s Board of Directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s Board of Directors in its sole discretion. The final voting results are as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    52,697,618   1,559,976   29,735   0

    Proposal 3. Ratification of the appointment of the independent registered public accounting firm.

    The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Crowe LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    54,274,675   5,234   7,420   0

    Proposal 4. Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation.

    The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 to 400,000,000 shares. The final voting results are as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    42,687,545   11,570,307   29,477   0

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

     3.1    Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company, dated May 28, 2026.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

            EQUILLIUM, INC.
    Date: May 29, 2026     By:  

    /s/ Bruce D. Steel

                Bruce D. Steel
                Chief Executive Officer
    Get the next $EQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EQ

    DatePrice TargetRatingAnalyst
    5/28/2026$6.00Market Perform → Outperform
    Leerink Partners
    4/23/2026$7.00Outperform
    Oppenheimer
    4/16/2026$6.00Buy
    B. Riley Securities
    4/14/2026$6.00Strong Buy
    Raymond James
    4/7/2026$10.00Overweight
    Cantor Fitzgerald
    3/13/2026$12.00Buy
    Roth Capital
    2/25/2026$5.00Buy
    Stifel
    3/28/2025$3.00 → $1.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $EQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Tom Penny sold $191,750 worth of shares (65,000 units at $2.95) as part of a pre-agreed trading plan and exercised 65,000 shares at a strike of $0.79 (SEC Form 4)

    4 - Equillium, Inc. (0001746466) (Issuer)

    5/29/26 6:28:50 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Demski Martha J

    4 - Equillium, Inc. (0001746466) (Issuer)

    5/29/26 6:27:09 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pruzanski Mark

    4 - Equillium, Inc. (0001746466) (Issuer)

    5/29/26 6:25:11 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June 1, 2026, the Compensation Committee of Equillium's Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 145,000 shares of common stock to a new employee under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price per share equal to $3.08, Equ

    6/2/26 4:05:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

    LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55pm EDT. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders. For more information, visit www.equilliumbio.com.

    5/28/26 4:05:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

    LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it will host a virtual investor event on Wednesday, May 27, 2026, at 11:00 AM ET. The event will be presented by Stephen Connelly Ph.D., Equillium's Chief Scientific Officer, and include new preclinical data evaluating several clinically relevant AhR modulators and further characterization of the relationship between AhR activation and miR-124 induction in both immune and epithelial cells. AhR is a xenosensor essential for maintaining intestinal barrier function and immune homeostasis an

    5/20/26 4:05:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Equillium upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Equillium from Market Perform to Outperform and set a new price target of $6.00

    5/28/26 8:44:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Equillium with a new price target

    Oppenheimer initiated coverage of Equillium with a rating of Outperform and set a new price target of $7.00

    4/23/26 7:55:51 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Equillium with a new price target

    B. Riley Securities initiated coverage of Equillium with a rating of Buy and set a new price target of $6.00

    4/16/26 9:01:30 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    SEC Filings

    View All

    SEC Form 8-K filed by Equillium Inc.

    8-K - Equillium, Inc. (0001746466) (Filer)

    5/29/26 4:05:29 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Equillium Inc.

    10-Q - Equillium, Inc. (0001746466) (Filer)

    5/13/26 4:10:34 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Equillium, Inc. (0001746466) (Filer)

    5/13/26 4:05:19 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Leadership Updates

    Live Leadership Updates

    View All

    Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights

    Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer to lead clinical development and medical strategy Cash and cash equivalents expected to fund currently planned operations into 2029 LA JOLLA, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update hi

    5/13/26 4:01:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

    SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. "We are thrilled to welcome Dan to NeuraClick," said Dr. Subhi Marwari, Chief Executive Officer. "For an early-stage venture, experienced guidance is essential, and Dan's deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigat

    9/23/25 5:30:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium to be included in the Russell Microcap® Index

    Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and va

    6/12/24 8:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Financials

    Live finance-specific insights

    View All

    Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

    Treatment with itolizumab did not improve complete or overall response rates at Day 29 Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics

    3/27/25 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Maintains Rights to Itolizumab Following Ono Partnership

    Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium's rights to itolizumab

    10/31/24 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

    Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone payments Ono to fund Equillium's continued research and development of itolizumab during the exercise period Conference call and webcast today at 8:30 a.m. ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. ("Ono"), today announced an option and asset purchase agreement through which Ono gains the exclusive option to

    12/6/22 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Equillium Inc.

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    11/14/24 9:50:36 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Equillium Inc.

    SC 13G - Equillium, Inc. (0001746466) (Subject)

    1/19/24 6:03:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Equillium Inc. (Amendment)

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    3/3/23 9:27:36 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care